TEAM & LEADERSHIP
Experienced Leadership. Specialized Expertise. Capital-Efficient Execution.
SELEQUIN Therapeutics brings together experienced scientists, oncology experts and business professionals. Our lean operating model combines strong internal scientific leadership with specialized external development expertise.
Prof. Dr.
Karl-Anton Kreuzer
Co-Founder & Scientific Lead
Clinical oncologist and hematology expert with extensive experience in translational and clinical cancer research. Co-founder of SELEQUIN and a driving force behind the scientific development of the platform.
Prof. Dr.
Albrecht Berkessel
Co-Founder & Chemistry Lead
Internationally recognized expert in synthetic and organic chemistry, co-inventor of the SELEOUIN platform and responsible for medicinal chemistry, compound development and|Pexpansion.
Dr.Jochen Antel
Chief Scientific Officer
Experienced pharmaceutical R&D executive with extensive drug-development expertise. More than 17 compounds advanced into Phase 1 clinical development. Responsible for development strategy, R&D and regulatory planning.
Dr. Katja Poredda
Postdoctoral Researcher
Her research focuses an the SELEQUIN platform.She coordinätes external research collaborations and supports translational research, preclinical development and project execution.
Dr. h.c.
Andreas Goldberg
Chief Executive Officer
Corporatestrategy,business development, strategic partnerships, fundraising and company leadership.
Dipl.-Kfm.
Michael Güttes
Investor Relations & Financing
Investor relations, fundraising, strategic partnerships and financing strategy.
Klaus Möllerfriedrich
Finance & Compliance
Finance and controlling, compliance, risk management, gowernance and reporting.
Dr. Alexander
Schröder-Frerkes
Chairman of the
Supervisory Board
Dr.
Elke Lieb
Member of the
Superwisory Board
Prof. Dr.
Michael Hallek
Chairman, Scientific Advisory Board
Internationally recognized physician-scientist and leading expert in hematology and oncology, with particularexpertise inCLL and translational cancer research.
SELEQUIN operates with a lean, capital-efficient development model. Specialized external partners provide
expertise and infrastructure across chemistry, preclinical development, CMC/GMPF, requlatory affairs and clinical operations.
Our model combines strong internal scientific leadership with specialized external expertise –
enabling flexible, milestone-driven and capital-efficient development.